• Je něco špatně v tomto záznamu ?

SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis

BAC. Cree, R. Maddux, A. Bar-Or, HP. Hartung, A. Kaur, E. Brown, Y. Li, Y. Hu, JK. Sheffield, D. Silva, S. Harris

. 2023 ; 10 (10) : 1725-1737. [pub] 20230807

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24001168

OBJECTIVE: To investigate the serologic response, predictors of response, and clinical outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis (RMS) from DAYBREAK. METHODS: DAYBREAK (ClinicalTrials.gov-NCT02576717), an open-label extension study of oral ozanimod 0.92 mg, enrolled participants aged 18-55 years with RMS who completed phase 1-3 ozanimod trials. Participants who were fully vaccinated against SARS-CoV-2 with mRNA or non-mRNA vaccines, were unvaccinated, and/or had COVID-19-related adverse events (AEs, with or without vaccination) and postvaccination serum samples were included (n = 288). Spike receptor binding domain (RBD) antibody levels (seroconversion: ≥0.8 U/mL) and serologic evidence of SARS-CoV-2 infection (nucleocapsid IgG: ≥1 U/mL) were assessed (Roche Elecsys/Cobas e411 platform). RESULTS: In fully vaccinated participants (n = 148), spike RBD antibody seroconversion occurred in 90% (n = 98/109) of those without serologic evidence of prior SARS-CoV-2 exposure (100% [n = 80/80] seroconversion after mRNA vaccination) and in 100% (n = 39/39) of participants with serologic evidence of viral exposure. mRNA vaccination predicted higher spike RBD antibody levels, whereas absolute lymphocyte count (ALC), age, body mass index, and sex did not. COVID-19-related AEs were reported in 10% (n = 15/148) of fully vaccinated participants-all were nonserious and not severe; all participants recovered. INTERPRETATION: Most ozanimod-treated participants with RMS mounted a serologic response to SARS-CoV-2 vaccination and infection, regardless of participant characteristics or ALC levels. In this analysis, all COVID-19-related AEs post-full vaccination in participants taking ozanimod were nonserious and not severe.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001168
003      
CZ-PrNML
005      
20240213094414.0
007      
ta
008      
240109s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/acn3.51862 $2 doi
035    __
$a (PubMed)37550942
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Cree, Bruce A C $u Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA $1 https://orcid.org/0000000176892533
245    10
$a SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis / $c BAC. Cree, R. Maddux, A. Bar-Or, HP. Hartung, A. Kaur, E. Brown, Y. Li, Y. Hu, JK. Sheffield, D. Silva, S. Harris
520    9_
$a OBJECTIVE: To investigate the serologic response, predictors of response, and clinical outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis (RMS) from DAYBREAK. METHODS: DAYBREAK (ClinicalTrials.gov-NCT02576717), an open-label extension study of oral ozanimod 0.92 mg, enrolled participants aged 18-55 years with RMS who completed phase 1-3 ozanimod trials. Participants who were fully vaccinated against SARS-CoV-2 with mRNA or non-mRNA vaccines, were unvaccinated, and/or had COVID-19-related adverse events (AEs, with or without vaccination) and postvaccination serum samples were included (n = 288). Spike receptor binding domain (RBD) antibody levels (seroconversion: ≥0.8 U/mL) and serologic evidence of SARS-CoV-2 infection (nucleocapsid IgG: ≥1 U/mL) were assessed (Roche Elecsys/Cobas e411 platform). RESULTS: In fully vaccinated participants (n = 148), spike RBD antibody seroconversion occurred in 90% (n = 98/109) of those without serologic evidence of prior SARS-CoV-2 exposure (100% [n = 80/80] seroconversion after mRNA vaccination) and in 100% (n = 39/39) of participants with serologic evidence of viral exposure. mRNA vaccination predicted higher spike RBD antibody levels, whereas absolute lymphocyte count (ALC), age, body mass index, and sex did not. COVID-19-related AEs were reported in 10% (n = 15/148) of fully vaccinated participants-all were nonserious and not severe; all participants recovered. INTERPRETATION: Most ozanimod-treated participants with RMS mounted a serologic response to SARS-CoV-2 vaccination and infection, regardless of participant characteristics or ALC levels. In this analysis, all COVID-19-related AEs post-full vaccination in participants taking ozanimod were nonserious and not severe.
650    _2
$a lidé $7 D006801
650    12
$a COVID-19 $7 D000086382
650    _2
$a vakcíny proti COVID-19 $x škodlivé účinky $7 D000086663
650    12
$a roztroušená skleróza $7 D009103
650    _2
$a SARS-CoV-2 $7 D000086402
650    _2
$a messenger RNA $7 D012333
650    _2
$a vakcinace $x škodlivé účinky $7 D014611
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Maddux, Rachel $u Bristol Myers Squibb, Princeton, New Jersey, USA
700    1_
$a Bar-Or, Amit $u Department of Neurology, Center for Neuroinflammation, and Experimental Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
700    1_
$a Hartung, Hans-Peter $u Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany $u Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia $u Department of Neurology, Medical University of Vienna, Vienna, Austria $u Palacký University Olomouc, Olomouc, Czech Republic $1 https://orcid.org/0000000206146989 $7 nlk20050167624
700    1_
$a Kaur, Amandeep $u Bristol Myers Squibb, Princeton, New Jersey, USA
700    1_
$a Brown, Elizabeth $u Bristol Myers Squibb, Princeton, New Jersey, USA $1 https://orcid.org/0000000208323758
700    1_
$a Li, Yicong $u Bristol Myers Squibb, Princeton, New Jersey, USA
700    1_
$a Hu, Yanhua $u Bristol Myers Squibb, Princeton, New Jersey, USA
700    1_
$a Sheffield, James K $u Bristol Myers Squibb, Princeton, New Jersey, USA
700    1_
$a Silva, Diego $u Bristol Myers Squibb, Princeton, New Jersey, USA
700    1_
$a Harris, Sarah $u Bristol Myers Squibb, Princeton, New Jersey, USA
773    0_
$w MED00189500 $t Annals of clinical and translational neurology $x 2328-9503 $g Roč. 10, č. 10 (2023), s. 1725-1737
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37550942 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213094411 $b ABA008
999    __
$a ok $b bmc $g 2049646 $s 1210862
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 10 $c 10 $d 1725-1737 $e 20230807 $i 2328-9503 $m Annals of clinical and translational neurology $n Ann Clin Transl Neurol $x MED00189500
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace